---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-012683"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-03-25T23:59:59+00:00"
generated_at: "2026-05-15T09:02:05.297015+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Technologies announces virtual physician roundtable on CyPath® Lung for April 8, 2026

## Summary
- Webinar titled 'CyPath® Lung in Practice: A Physician Roundtable Discussion' on April 8, 2026 at 7 p.m. ET.
- Moderated by CMO Gordon H. Downie, MD, PhD; panel includes three pulmonologists sharing real-world cases.
- CyPath® Lung achieved 92% sensitivity, 87% specificity, 88% accuracy in detecting lung cancer in high-risk patients with small nodules.
- First of a series aimed at integrating noninvasive CyPath® Lung into pulmonary practice for nodule management.

## SEC filing metadata
- accession: 0001493152-26-012683
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-03-25T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226012683/0001493152-26-012683-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226012683/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-012683
- JSON: https://secwatch.observer/filing/0001493152-26-012683.json
- Plain text: https://secwatch.observer/filing/0001493152-26-012683.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.